Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keith Stewart

Showing results (101-110 of 208) with videos related to

Pageof 21
Sort By:
Journal of Clinical Pharmacology|December 8, 2016
Population Pharmacokinetics and Exposure-Response Relationship of Carfilzomib in Patients With Multiple MyelomaYing Ou, Sameer Doshi, Anh Nguyen, et al.
Blood|March 17, 2012
Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myelomaShaji Kumar, Ian Flinn, Paul G Richardson, et al.
Clinical Lymphoma & Myeloma|April 14, 2009
High-resolution genomic analysis in Waldenström's macroglobulinemia identifies disease-specific and common abnormalities with marginal zone lymphomasEsteban Braggio, Jonathan J Keats, Xavier Leleu, et al.
Cancer Chemotherapy and Pharmacology|March 23, 2010
Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myelomaDonna E Reece, Dan Sullivan, Sagar Lonial, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|March 23, 2023
Clonal Hematopoiesis of Indeterminate Potential Is Associated With Coronary Microvascular Dysfunction In Early Nonobstructive Coronary Artery DiseaseNadia Akhiyat, Terra Lasho, Morsaleh Ganji, et al.
Blood Cancer Journal|April 5, 2023
Prognostic value of early bone marrow MRD status in CAR-T therapy for myelomaRadhika Bansal, Mizba Baksh, Jeremy T Larsen, et al.
Leukemia|January 31, 2019
Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenanceShaji K Kumar, Jesus G Berdeja, Ruben Niesvizky, et al.
Oncotarget|January 2, 2018
Combined venetoclax and alvocidib in acute myeloid leukemiaJames Bogenberger, Clifford Whatcott, Nanna Hansen, et al.
Mayo Clinic Proceedings|July 2, 2019
Clinical Applications and Utility of a Precision Medicine Approach for Patients With Unexplained CytopeniasAbhishek A Mangaonkar, Alejandro Ferrer, Filippo Pinto E Vairo, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 14, 2018
Treatment With Bortezomib-based Therapy, Followed by Autologous Stem Cell Transplantation, Improves Outcomes in Light Chain Amyloidosis: A Retrospective StudyTania Jain, Heidi E Kosiorek, Shu T Kung, et al.
Pageof 21

Showing results (101-110 of 208) with videos related to

Sort By:
Pageof 21
Journal of Clinical Pharmacology|December 8, 2016
Population Pharmacokinetics and Exposure-Response Relationship of Carfilzomib in Patients With Multiple MyelomaYing Ou, Sameer Doshi, Anh Nguyen, et al.
Blood|March 17, 2012
Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myelomaShaji Kumar, Ian Flinn, Paul G Richardson, et al.
Clinical Lymphoma & Myeloma|April 14, 2009
High-resolution genomic analysis in Waldenström's macroglobulinemia identifies disease-specific and common abnormalities with marginal zone lymphomasEsteban Braggio, Jonathan J Keats, Xavier Leleu, et al.
Cancer Chemotherapy and Pharmacology|March 23, 2010
Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myelomaDonna E Reece, Dan Sullivan, Sagar Lonial, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|March 23, 2023
Clonal Hematopoiesis of Indeterminate Potential Is Associated With Coronary Microvascular Dysfunction In Early Nonobstructive Coronary Artery DiseaseNadia Akhiyat, Terra Lasho, Morsaleh Ganji, et al.
Blood Cancer Journal|April 5, 2023
Prognostic value of early bone marrow MRD status in CAR-T therapy for myelomaRadhika Bansal, Mizba Baksh, Jeremy T Larsen, et al.
Leukemia|January 31, 2019
Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenanceShaji K Kumar, Jesus G Berdeja, Ruben Niesvizky, et al.
Oncotarget|January 2, 2018
Combined venetoclax and alvocidib in acute myeloid leukemiaJames Bogenberger, Clifford Whatcott, Nanna Hansen, et al.
Mayo Clinic Proceedings|July 2, 2019
Clinical Applications and Utility of a Precision Medicine Approach for Patients With Unexplained CytopeniasAbhishek A Mangaonkar, Alejandro Ferrer, Filippo Pinto E Vairo, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 14, 2018
Treatment With Bortezomib-based Therapy, Followed by Autologous Stem Cell Transplantation, Improves Outcomes in Light Chain Amyloidosis: A Retrospective StudyTania Jain, Heidi E Kosiorek, Shu T Kung, et al.
Pageof 21